Diverse mix of Human MoAbs to treat Anthrax exposure

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$100,000.00
Award Year:
2003
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI052901-01A1
Award Id:
65932
Agency Tracking Number:
AI052901
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
AVANIR PHARMACEUTICALS, 11388 SORRENTO VALLEY RD, STE 200, SAN DIEGO, CA, 92121
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
PHILLIPMORROW
(858) 622-5257
PMORROW@AVANIR.COM
Business Contact:
DAVIDHANSEN
(858) 622-5215
DHANSEN@AVANIR.COM
Research Institute:
n/a
Abstract
DESCRIPTION (provided by the applicant): The long-term goal of this proposal (phase I and II) is the development of a human monoclonal antibody-based preparation for use in treating B. anthracis (anthrax) exposure or for use prophylactically. This preparation would most likely be composed of multiple, different monoclonal antibodies. Such a preparation would fill a significant void in the arsenal of reagents available to treat this biowarfare threat. Phase I specific aims are: 1) Evaluate the human antibody response of peripheral blood leukocytes from AVA vaccinated donors in the human lymphocyte engrafted SCID mouse (hu-PBL-SCID system). Immunogens will include a) recombinant Protective Antigen (PA), b) the active fragment of PA, c) Lethal Factor (LF), and (optionally) d) the Lethal Toxin formed from PA+LF. Antigen specific serum human antibodies will be detected by 'ELISA, and neutralizing antibody levels will be measured using the murine macrophage cell line RAW. 2) Evaluate Lethal Toxin treatment as an in vivo approach to select mice making neutralizing antibodies. 3) Generate, from selected animals, an initial series of human monoclonal antibodies specific for PA, and possibly LF. These will be characterized for neutralizing activity, and using BIACORE, affinity and epitope grouping. The main goal of the phase II proposal will be the configuration of at least one combination of human monoclonals which could be evaluated in vivo for the ability to protect and/or rescue from B. anthracis challenge. The phase II SBIR program may require the generation of a larger panel of antibodies, based on the success of phase I.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government